

## Amended Appendix 3Y

Further to the Appendix 3Y released on 30 January 2024 for Dr Thomas Duthy, please note the attached Amended Appendix 3Y which is relodged to correct an error to the trading account name held by Dr Duthy.

No other changes were made.

### Authority

This announcement has been authorised for release by the Company Secretary of Neurotech International Limited.

### Investors:

Dr Thomas Duthy  
Executive Director  
td@neurotechinternational.com  
+61 (0)402 493 727

### About Neurotech

**Neurotech International Limited (ASX:NTI)** is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders. Neurotech has completed a Phase I/II clinical trial in Autism Spectrum Disorder (ASD), which demonstrated excellent safety and efficacy results at 28 days, 20 weeks and 52 weeks of treatment with NTI164. The Company has commenced a Phase II/III randomised, double-blind, placebo-controlled clinical trial in ASD and additional Phase I/II trials in Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS, along with Rett Syndrome during CY2023. Neurotech is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Neurotech International Limited
<b>ABN</b>	73 610 205 402

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Thomas Duthy
<b>Date of last notice</b>	28 December 2022

#### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Dr Thomas Duthy is a Director and Shareholder of Emmirato Pty Ltd.
<b>Date of change</b>	29 January 2024
<b>No. of securities held prior to change</b>	<u>CIPA Investments Pty Ltd &lt;CIPA Investments A/C&gt;:</u> 10,000,000 NTIOPT18 Unlisted Options (\$0.10, 23 December 2027) 10,000,000 NTIOPT19 Unlisted Options (\$0.15, 23 December 2027)
<b>Class</b>	NTI Ordinary Shares
<b>Number acquired</b>	340,000 NTI Ordinary Shares
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$30,820

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held after change</b>	<p>CIPA Investments Pty Ltd &lt;CIPA Investments A/C&gt;:</p> <p>10,000,000 NTIOPT18 Unlisted Options (\$0.10, 23 December 2027)</p> <p>10,000,000 NTIOPT19 Unlisted Options (\$0.15, 23 December 2027)</p> <p>Emmirato Pty Ltd:</p> <p>340,000 NTI Ordinary Shares</p>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	On-market purchase.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
---	----

<sup>+</sup> See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

+ See chapter 19 for defined terms.